CO-Administration of lipiodol does not affect pharm acokinetics, toxicity, or efficacy of intra-arterial adriamycin in patients with hepatocellular carcinoma (HCC)

Pj Johnson,C Kalayci,E Metivier,P Harper,N Dobbs,N Raby,Roger Williams

doi:10.1016/0168-8278(90)91464-8

CO-Administration of lipiodol does not affect pharm acokinetics, toxicity, or efficacy of intra-arterial adriamycin in patients with hepatocellular carcinoma (HCC)

Pj Johnson, C Kalayci + Show 5 more

https://doi.org/10.1016/0168-8278(90)91464-8

Copy DOI

Export

Save

Cite

Journal: Journal of Hepatology

Publication Date: Jan 1, 1990

#Adriamycin In Patients #Toxicity Of Adriamycin #Hepatocellular Carcinoma #Intra-arterial Adriamycin #Pharmacokinetics

Abstract
Full-Text
Similar Papers

Abstract

Listen

CO-Administration of lipiodol does not affect pharm acokinetics, toxicity, or efficacy of intra-arterial adriamycin in patients with hepatocellular carcinoma (HCC)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Hepatology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

CO-Administration of lipiodol does not affect pharm acokinetics, toxicity, or efficacy of intra-arterial adriamycin in patients with hepatocellular carcinoma (HCC)